Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Oncopeptides obtains reimbursement for Pepaxti in Italy Regulatory

November 27, 2024
Stockholm, November 27, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that it has come to an agreement with the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) on the pricing and reimbursement of melflufen, branded in Europe as Pepaxti. The decision paves the way for the drug to be commercialized in Italy during H1, 2025
Read more

Oncopeptides announces the Nomination Committee Regulatory

November 22, 2024
Stockholm – November 22, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established
Read more

Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting

November 20, 2024
Stockholm – November 20, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10
Read more

Oncopeptides publishes Q3 report 2024 Regulatory

November 7, 2024
Stockholm – November 7, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024
Read more

Invitation to presentation of the Q3 report 2024

October 31, 2024
Stockholm – October 31, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter of 2024, at 08:00 CET on November 7, 2024
Read more

Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea

September 12, 2024
Stockholm, September 12, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea
Read more

Oncopeptides publishes Q2 report 2024 Regulatory

August 14, 2024
Stockholm – August 14, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2024
Read more

Invitation to presentation of the Q2 report 2024

August 8, 2024
Stockholm – August 8, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the second quarter of 2024, at 08:00 CET on August 14, 2024
Read more

First patient enters Oncopeptides study aiming to gain real-world insights from Pepaxti in Germany

July 22, 2024
Stockholm, July 22, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients. The study, which will include 100 patients across around 50 sites in Germany, aims at gathering evidence on Pepaxti’s effectiveness and safety in a real-world clinical practice and is the first Pepaxti study engaging treating physicians at multiple German sites
Read more

Number of shares and votes in Oncopeptides Regulatory

June 28, 2024
STOCKHOLM – June 28, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 238,107 class C shares in Oncopeptides to a total 238,107 ordinary shares, in order to deliver ordinary shares to participants in Oncopeptides’ incentive program Board SHP 2023
Read more